Literature DB >> 11574816

Histamine stimulates alveolar macrophages to release neutrophil and monocyte chemotactic activity.

H Nomura1, E Sato, S Koyama, M Haniuda, K Kubo, S Nagai, T Izumi.   

Abstract

Histamine and serotonin are important inflammatory mediators in the pathophysiology of asthma, and asthmatic patients have higher plasma histamine and serotonin levels than non-asthmatic control subjects. Alveolar macrophages (AMs) synthesize and secrete a large number of substances that play a key role in acute and chronic inflammation including asthma. We postulated that AMs might release chemotactic activity for neutrophils and monocytes in response to histamine or serotonin. To test this hypothesis, bovine AMs were cultured, and the supernatant fluids were evaluated for neutrophil chemotactic activity (NCA) and monocyte chemotactic activity (MCA) by a blind well chamber technique. AMs released chemotactic activity in response to histamine and serotonin in a dose- and time-dependent manner (P <.05). Partial characterization and molecular sieve column chromatography revealed that low-molecular-weight lipid-soluble activity was predominant. Lipoxygenase inhibitors significantly blocked the release of chemotactic activity. Leukotriene B(4) receptor antagonists blocked the chemotactic activity. Immunoreactive leukotriene B(4) significantly increased in supernatant fluids in response to histamine and serotonin. The receptor responsible for the release of chemotactic activity in response to histamine was the H2 receptor. These data demonstrate that AMs release NCA and MCA in response to histamine or serotonin (or both) and may modulate the inflammatory cell recruitment into the lung.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574816     DOI: 10.1067/mlc.2001.117988

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  5 in total

1.  Serotonin upregulates the activity of phagocytosis through 5-HT1A receptors.

Authors:  M Freire-Garabal; M J Núñez; J Balboa; P López-Delgado; R Gallego; T García-Caballero; M D Fernández-Roel; J Brenlla; M Rey-Méndez
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

2.  Is low dose inhaled corticosteroid therapy as effective for inflammation and remodeling in asthma? A randomized, parallel group study.

Authors:  Melissa Baraket; Brian G G Oliver; Janette K Burgess; Sam Lim; Gregory G King; Judith L Black
Journal:  Respir Res       Date:  2012-02-02

Review 3.  Immunomodulatory effects mediated by serotonin.

Authors:  Rodrigo Arreola; Enrique Becerril-Villanueva; Carlos Cruz-Fuentes; Marco Antonio Velasco-Velázquez; María Eugenia Garcés-Alvarez; Gabriela Hurtado-Alvarado; Saray Quintero-Fabian; Lenin Pavón
Journal:  J Immunol Res       Date:  2015-04-19       Impact factor: 4.818

Review 4.  The Interplay between Host Immunity and Respiratory Viral Infection in Asthma Exacerbation.

Authors:  Ferdaus Mohd Altaf Hossain; Jin Young Choi; Erdenebileg Uyangaa; Seong Ok Park; Seong Kug Eo
Journal:  Immune Netw       Date:  2019-09-09       Impact factor: 6.303

5.  Diethylcarbamazine attenuates the development of carrageenan-induced lung injury in mice.

Authors:  Edlene Lima Ribeiro; Karla Patricia de Souza Barbosa; Ingrid Tavares Fragoso; Mariana Aragão Matos Donato; Fabiana Oliveira dos Santos Gomes; Bruna Santos da Silva; Amanda Karolina Soares e Silva; Sura Wanessa Santos Rocha; Valdemiro Amaro da Silva Junior; Christina Alves Peixoto
Journal:  Mediators Inflamm       Date:  2014-01-16       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.